Navigation Links
Advances in Inflammatory Bowel Disease -- what's new, what's next
Date:3/22/2013

Philadelphia, Pa. (March 22, 2013) Every five years, the Crohn's & Colitis Foundation of America (CCFA) gathers top researchers in inflammatory bowel disease (IBD) to set the research agenda for the next five years. The findings and recommendations of these expert workgroups are presented in a series of detailed "Challenges in IBD Research" reports, now available in Inflammatory Bowel Diseases, official journal of the CCFA. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

Each workgroup is assigned to specific topic areas including genetics, epidemiology and environmental factors, the "microbiome" (intestinal bacteria), epithelial cell biology, innate and adaptive immunity, clinical classification and prognostic models, and optimizing medical therapy. A special "Challenges in IBD Research" progress report appears in the March issue of Inflammatory Bowel Diseases. The complete workgroup reports are available for direct download at http://links.lww.com/IBD/A77.

Experts Outline New Agenda for IBD Research

Based on a thorough review in each area, the workgroups have defined key research priorities for the next few years, including:

  • Defining clinically relevant subgroups of IBD patientsusing different types of information to predict aggressiveness of disease, complications, and response to treatment.

  • Understanding the environmental factors affecting the risk and course of IBDincluding environmental "triggers" and a specific focus on the role of diet.

  • Clarifying the complex interrelationships among genes, bacteria, and epithelial and immune responsesfocusing on cellular pathways and critical cell types that may lead to new "therapeutic targets."

  • Determining the optimal treatment approaches and strategies through comparative effectiveness studies.

The workgroup reports also identify the resources needed to carry out this ambitious research agenda, including a "centralized and distributable infrastructure" for integrated studies of IBD in humans and long-term follow-up studies of children and adults with IBD.

"Through development of the ambitious research goals outlined in this document, the Crohn's & Colitis Foundation of America has again led the effort to further the understanding of IBD," said Dr. Lee Denson of Cincinnati Children's Hospital Medical Center. "CCFA is keen to advance this research agenda in 2013 and beyond."

Building on Recent Scientific and Clinical Advances

The CCFA research agenda builds on recent advances in scientific and clinical research. They include major strides in IBD geneticsmore than 160 genes affecting susceptibility to Crohn's disease and ulcerative colitis have now been identified. Using sophisticated techniques, researchers have gained new insights into the complex interactions between intestinal bacteria and immune responses, including the role of specific types of immune cells.

Clinical studies have improved the ability to predict the response to IBD treatment in children and to track the short- and long-term adverse effects of IBD treatments. Progress has also been made in understanding the risks and benefits of medical and surgical treatments for key patient subgroups, including pregnant women and newborns. These studies point the way toward future efforts to optimize treatment for individual patients with IBD.


'/>"/>

Contact: Connie Hughes
connie.hughes@wolterskluwer.com
646-674-6348
Wolters Kluwer Health
Source:Eurekalert

Related medicine news :

1. Gene Therapy for Human Disease: Clinical Advances and Challenges
2. UC Davis research advances efforts to prevent dangerous blood clots
3. Einstein researchers present on imaging advances
4. Pulmonary & Allergy Update highlights insights and advances
5. Expert Revivogen Provides Tips and Education to Prevent Hair Loss, Recommends Starting a Preventative Hair Loss Regimen to Stop the Condition Before it Advances
6. 2013 Gastrointestinal Cancers Symposium reveals new advances for GI cancers
7. USC Norris cancer research ranks among top clinical advances for 2012
8. Research from ASCOS Quality Care Symposium shows advances and challenges in improving the quality of cancer care
9. Collegiate inventors honored for innovative science and technology advances
10. Key research from the 2012 Breast Cancer Symposium highlights treatment advances for early breast cancer
11. Advances in ataxia research to be featured at USFs Innovative Learning and Simulation Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... 2016 , ... ‘Tis the season for giving! Today, 20 creative teams across ... Partnership and the Drug Enforcement Administration as part of the National Red Ribbon Week ... schools who decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. Be ...
(Date:11/30/2016)... PITTSBURGH, PA (PRWEB) , ... November 30, 2016 , ... ... my hand and arm while brushing my teeth," said an inventor from Bridgewater, N.J. ... led me to develop this handy device." , He developed the patent-pending DEFLECTOR to ...
(Date:11/30/2016)... ... 30, 2016 , ... Center For Discovery, a nationally recognized ... a new residential mental health treatment program in Chino Hills, California.  The California facility ... anxiety, depression, bi-polar disorder, and other related issues. , Center For Discovery is ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... the clinical research community that the FDA Binding Guidance goes into effect next ... FDA-supported formats listed in the FDA Data Standards Catalog. The current FDA Data ...
(Date:11/30/2016)... Beach, FL (PRWEB) , ... November 30, 2016 , ... ... staffing solutions, is proud to announce it was recently named the 2016 Provider and ... based on third-party client and caregiver satisfaction scores, and only providers with the highest ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2016 Allergan plc (NYSE: AGN ), ... its previously announced Accelerated Share Repurchase (ASR) Program. ... ... As previously announced, the Company entered into a variable tenor ... will repurchase $10 billion of its ordinary shares. Approximately 40.5 ...
(Date:11/30/2016)... 30, 2016 Research and Markets ... for Neuromodulation, Neurovascular, Neurosurgical and Monitoring Devices 2017 - MedView" ... ... The full report suite on the U.S. market for ... systems, intracranial pressure monitoring devices, detachable coils, liquid embolics, catheters, ...
(Date:11/30/2016)... , Nov. 30, 2016 Varian Medical ... was named America,s Most JUST Company in the Healthcare ... Forbes magazine,s inaugural "JUST 100 List." The ... the largest surveys ever conducted on attitudes towards corporate ... This inaugural list ranks U.S companies against their peers ...
Breaking Medicine Technology: